Rigel Pharmaceuticals Reports Strong 2024 Financial Results

Rigel Pharmaceuticals ( (RIGL) ) has released its Q4 earnings. Here is a breakdown of the information Rigel Pharmaceuticals presented to its investors.

Rigel Pharmaceuticals, Inc. is a biotechnology company specializing in the development and commercialization of therapies for hematologic disorders and cancer. Based in South San Francisco, the company is recognized for its innovative approach in the biotech sector.

In its latest earnings report, Rigel Pharmaceuticals announced a significant increase in both quarterly and annual revenues for 2024, driven by strong sales of its key products TAVALISSE, REZLIDHIA, and GAVRETO. The company also highlighted its strategic advancements in clinical development and international market expansion.

Rigel’s total revenue for the fourth quarter of 2024 reached $57.6 million, with notable contributions from TAVALISSE, REZLIDHIA, and GAVRETO. For the full year, the company reported $179.3 million in revenue, marking a 39% increase from the previous year. Rigel achieved a net income of $17.5 million for 2024, a significant turnaround from a net loss in 2023. The company also secured regulatory milestones and expanded its clinical trials, including the advancement of R289 and olutasidenib studies.

The company’s strategic initiatives include a partnership with Dr. Reddy’s Laboratories for the development of REZLIDHIA in various global markets and the continued clinical evaluation of R289. Rigel’s efforts in expanding its product reach and advancing its clinical pipeline are supported by its robust financial performance.

Looking ahead, Rigel Pharmaceuticals projects total revenue of $200 to $210 million for 2025, with expectations of positive net income. The company remains focused on expanding its commercial portfolio and advancing its hematology and oncology pipeline, positioning itself for continued growth in the biotech industry.